# Carbapenem PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/carbapenem

> Carbapenem, sponsored by Innoviva, Inc. (INVA): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | carbapenem |
| Codes |  |
| Sponsor | Innoviva, Inc. (INVA) https://sec-api.dev/companies/inva/catalysts |
| Indications | with carbapenem-resistant acinetobacter infections, with positive top-line data |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: with carbapenem-resistant Acinetobacter infections, with positive top-line data.
- First seen 2025-02-26, last confirmed 2026-02-25.
- SEC Form 10-K (accession 0001193125-26-071776): "We completed ATTACK, a Phase 3 registration trial of XACDURO® for the treatment of patients with carbapenem-resistant Acinetobacter infections, with positive top-line data announced in October 2021 and published in The Lancet Infectious Diseases in May 2023." https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm
- SEC Form 10-K (accession 0000950170-25-027864): "We completed ATTACK, a Phase 3 registration trial of XACDURO for the treatment of patients with carbapenem-resistant Acinetobacter infections, with positive top-line data announced in October 2021 and published in The Lancet Infectious Diseases in May 2023." https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-20241231.htm

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-01-10, last confirmed 2025-01-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004063): "2H 2025 milestones  Strong global intellectual  Phase 3 data readout and property regulatory submission (US) expected in 2H 20251  GSK commercial partnership with strong economics" https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/d820907dex991.htm

### June 18, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-06-22, last confirmed 2026-06-22.
- SEC Form 8-K (accession 0001193125-26-277506): "FDA approval was received in advance of FDA-assigned Prescription Drug User Fee Act ("PDUFA") date of June 18, 2026." https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395d8k.htm

Calendar months: [June 2026](https://sec-api.dev/fda-calendar/2026-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/carbapenem.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Carbapenem PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/carbapenem

```bibtex
@misc{secapidev_pdufa_carbapenem_20261116,
  title        = {Carbapenem PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/carbapenem}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_carbapenem_20261116","title":"Carbapenem PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/carbapenem","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
